4basebio Plc Joint Development Agreement with Heqet Therapeutics
April 27 2022 - 2:00AM
UK Regulatory
TIDM4BB
27 April 2022
4basebio PLC
("4basebio", the "Company" or the "Group")
Joint Development Agreement with Heqet Therapeutics
for development of a non-viral vector therapy for cardiac regeneration
4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting
intellectual property in the field of cell and gene therapies and DNA and mRNA
vaccines, is pleased to announce a Joint Development Agreement ("JDA") with
Heqet Therapeutics S.r.l. ("Heqet"). This JDA is focussed on the development
of a non-viral vector, incorporating a proprietary Heqet payload for
cardiomyocyte regeneration and treatment of myocardial infarction more broadly.
Heqet recently closed an ?8m financing round to progress its development
programmes. It is using its proprietary intellectual property to develop
therapies which enable heart regeneration and renewal, thereby avoiding scar
formation on the heart post myocardial infarction. Such scarring can eventually
lead to cardiac dysfunction and failure, despite improvements in medical
interventions.
Under the JDA, the companies will evaluate the use of 4basebio's HermesT
non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte
regeneration. The successful outcome of this project may lead to the
proof-of-concept development of a therapy enabling heart regeneration post
infarction.
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: "We are delighted to be
working with Heqet on this novel therapy approach for heart repair following
myocardial infarction. This further demonstrates the flexible application of
our HermesT targeted delivery technology within the cell and gene therapy
markets."
Dr Marta Antonucci, CEO of Heqet, said: "We are delighted to be working with
4basebio in developing a vector targeting cardiomyocyte regeneration. 4basebio
and Heqet bring complementary expertise and technologies to this exciting
program."
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396
7943
Heikki Lanckriet
Nominated Adviser +44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker +44 (0)20
7220 0500
finnCap Ltd
Geoff Nash/Richard Chambers/Charlotte Sutcliffe
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery of
payloads. The immediate objectives of 4basebio are to continue the validation
of its DNA products and HermesT technology and commence revenue generation
during 2022. 4basebio also continues to advance its collaborations to
facilitate the functional validation of its DNA based products and cell and
gene delivery solutions.
About Heqet
Heqet Therapeutics is an early-stage biotech company focussed on developing
novel RNAi therapeutics to reverse the damage created by ischemic heart
disease, the leading cause of death worldwide. The company is using the
proceeds from its successful financing round to execute its pre-clinical plan
and advance its programs towards clinical application.
Forward-looking statements
This announcement may contain certain statements about the future outlook for
the 4basebio. Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.
END
(END) Dow Jones Newswires
April 27, 2022 02:00 ET (06:00 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024
4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024